Cited by 4,110Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.

Epidemiology of Parkinson's disease

de Lau, Lonneke ML, Breteler, Monique MB·2006·The Lancet Neurology

DOI 10.1016/s1474-4422(06)70471-9

Open this paper in CoChat — free account

Abstract

The causes of Parkinson's disease (PD), the second most common neurodegenerative disorder, are still largely unknown. Current thinking is that major gene mutations cause only a small proportion of all cases and that in most cases, non-genetic factors play a part, probably in interaction with susceptibility genes. Numerous epidemiological studies have been done to identify such non-genetic risk factors, but most were small and methodologically limited. Larger, well-designed prospective cohort studies have only recently reached a stage at which they have enough incident patients and person-years of follow-up to investigate possible risk factors and their interactions. In this article, we review what is known about the prevalence, incidence, risk factors, and prognosis of PD from epidemiological studies.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(06)70471-9

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,770
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Eeden, S. K. V. D. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,805
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I. G., Quinn, N. P., Sethi, K. D., Shults, C. W., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,011
Parkinson Disease in Twins
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 876
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G., Widner, H., Mari�, R.-M., Rémy, P., & Levivier, M. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4 · Cited by 863
The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK
MacDonald, B. K. (2000) · Brain · doi:10.1093/brain/123.4.665 · Cited by 858

Show all 119 references

Research works printed but not linked: 3

Fink, 2001, Caffeine intake and the risk of incident Parkinson's disease: the Framingham Study, Mov Disord, 16, 984
Anderson, 1999, Dietary factors in Parkinson's disease: the role of food groups and specific foods, Mov Disord, 14, 21, 10.1002/1531-8257(199901)14:1<21::AID-MDS1006>3.0.CO;2-Y · DOI
De Lau LM, Koudstaal PJ, Witteman J, Hofman A, Breteler MM. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology (in press).

Sorted by citations

Items 201–300 of 1,019

Natural products attenuate PI3K/Akt/mTOR signaling pathway: A promising strategy in regulating neurodegeneration
Fakhri, S., Iranpanah, A., Gravandi, M. M., Moradi, S. Z., Ranjbari, M., Majnooni, M. B., Echeverría, J., Qi, Y., Wang, M., Liao, P., et al. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153664 · Cited by 161
Neuroprotective and Anti-inflammatory Activities of Ketogenic Diet on MPTP-induced Neurotoxicity
Yang, X., & Cheng, B. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9336-y · Cited by 159
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities
Berg, D., Lang, A. E., Postuma, R. B., Maetzler, W., Deuschl, G., Gasser, T., Siderowf, A. D., Schapira, A. H. V., Oertel, W. H., Obeso, J. A., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70047-4 · Cited by 164
Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology.
Borovac, J. A. (2016) · Europe PMC (PubMed Central) · Cited by 159
Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson’s disease
Karayel, Ö., Winter, S. V., Padmanabhan, S., Kuras, Y. I., Vu, D. T., Tuncali, I., Merchant, K., Wills, A.-M. A., Scherzer, C. R., & Mann, M. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100661 · Cited by 161
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies
Magalhães, P., & Lashuel, H. A. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00357-0 · Cited by 167
Metformin rescues Parkinson’s disease phenotypes caused by hyperactive mitochondria
Mor, D. E., Sohrabi, S., Kaletsky, R. L., Keyes, W., Tartici, A., Kalia, V., Miller, G. W., & Murphy, C. T. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009838117 · Cited by 155
“Parkinson ’ s disease | metformin | mitochondria | branched-chain amino acid metabolism | Caenorhabditis elegans P arkinson ’ s disease (PD) is the most common neurodegenerative movement disorder worldwide, and its prevalence is predicted to significantly increase as the population ages (1, 2).”
The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson’s Disease in Rats
Mao, Z., Liu, C., Ji, S., Yang, Q., Ye, H., Han, H., & Xue, Z. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2185-0 · Cited by 155
LRRK2 and Parkinson Disease
Dächsel, J. C., & Farrer, M. J. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.79 · Cited by 157
The Role of the Antioxidant Response in Mitochondrial Dysfunction in Degenerative Diseases: Cross-Talk between Antioxidant Defense, Autophagy, and Apoptosis
Huang, M., Chiang, S., Kalinowski, D. S., Bae, D.-H., Sahni, S., & Richardson, D. R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/6392763 · Cited by 155
“Parkinson’s disease (PD) is the second most common neurodegenerative disease after AD and affects 1% of the population above 60 years of age [130].”
Background
Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson’s disease
Sundaram, S., Hughes, R. L., Peterson, E., Müller-Oehring, E. M., Brontë-Stewart, H. M., Poston, K. L., Faerman, A., Bhowmick, C., & Schulte, T. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.05.016 · Cited by 152
Use of Calcium Channel Blockers and Parkinson’s Disease
Pasternak, B., Svanström, H., Nielsen, N. M., Fugger, L. H., Melbye, M., & Hviid, A. P. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kwr362 · Cited by 154
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology
Tsuang, D. W., Leverenz, J. B., López, O. L., Hamilton, R. L., Bennett, D. A., Schneider, J. A., Buchman, A. S., Larson, E. B., Crane, P. K., Kaye, J. A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182735e9a · Cited by 155
Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases
Cacciatore, I., Ciulla, M., Fornasari, E., Marinelli, L., & Stefano, A. D. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1178237 · Cited by 156
Oxidative Stress, Mitochondrial Dysfunction, and Neuroprotection of Polyphenols with Respect to Resveratrol in Parkinson’s Disease
Kung, H., Lin, K.-J., Kung, C., & Lin, T. (2021) · Biomedicines · doi:10.3390/biomedicines9080918 · Cited by 165
Cardiac abnormalities in Parkinson’s disease and Parkinsonism
Scorza, F. A., FIORINI, A. C., Scorza, C. A., & Finsterer, J. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.04.031 · Cited by 156
Urinary proteome profiling for stratifying patients with familial Parkinson’s disease
Winter, S. V., Karayel, Ö., Strauss, M. T., Padmanabhan, S., Surface, M., Merchant, K., Alcalay, R. N., & Mann, M. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013257 · Cited by 149
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial
Simuni, T., Fiske, B., Merchant, K., Coffey, C. S., Klingner, E., Caspell-Garcia, C., Lafontant, D.-E., Matthews, H., Wyse, R. K., Brundin, P., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4725 · Cited by 149
Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration
Andersen, H. H., Johnsen, K. B., & Moos, T. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1509-8 · Cited by 151
Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)
Dennison, E. M., Compston, J. E., Flahive, J., Siris, E. S., Gehlbach, S. H., Adachi, J. D., Boonen, S., Chapurlat, R. D., Díez‐Pérez, A., Anderson, F. A., et al. (2012) · Bone · doi:10.1016/j.bone.2012.02.639 · Cited by 148
“It has been reported that Parkinson's disease patients have a higher incidence of hip fractures than the general population [12,13].”
Background
Functional Connectivity Signatures of Parkinson’s Disease
Tessitore, A., Cirillo, M., & Micco, R. D. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191592 · Cited by 170
Recent mitochondrial DNA mutations increase the risk of developing common late-onset human diseases
Hudson, G., Gomez-Duran, A., Wilson, I. J., & Chinnery, P. F. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004369 · Cited by 148
Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease
Berg, D. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.141 · Cited by 149
Assessment of Speech Intelligibility in Parkinson’s Disease Using a Speech-To-Text System
Dimauro, G., Nicola, V. D., Bevilacqua, V., Caivano, D., & Girardi, F. (2017) · IEEE Access · doi:10.1109/access.2017.2762475 · Cited by 149
Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease
Palfi, S., Gurruchaga, J. M., Lepetit, H., Howard, K., Ralph, G. S., Mason, S., Gouello, G., Domenech, P., Buttery, P. C., Hantraye, P., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2018.081 · Cited by 158
A Comparative Study of Existing Machine Learning Approaches for Parkinson's Disease Detection
Pahuja, G., & Nagabhushan, T. N. (2018) · IETE Journal of Research · doi:10.1080/03772063.2018.1531730 · Cited by 148
Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease
Vila, M. (2019) · Movement Disorders · doi:10.1002/mds.27776 · Cited by 154
Parkinson’s disease and enhanced inflammatory response
Stojkovska, I., Wagner, B. M., & Morrison, B. E. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215576313 · Cited by 149
“2015–3:47pm] [1–9] //blrnas3.”
Clinical Criteria for the Diagnosis of Parkinson’s Disease
Reichmann, H. (2010) · Neurodegenerative Diseases · doi:10.1159/000314478 · Cited by 145
Biomarker Research in Parkinson’s Disease Using Metabolite Profiling
Havelund, J. F., Heegaard, N. H. H., Færgeman, N. J., & Gramsbergen, J. B. (2017) · Metabolites · doi:10.3390/metabo7030042 · Cited by 147
Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson’s Disease
Trupp, M., Jonsson, P., Öhrfelt, A., Zetterberg, H., Obudulu, O., Malm, L., Wuolikainen, A., Linder, J., Möritz, T., Blennow, K., et al. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-140389 · Cited by 140
“in motor function initiated by loss of at least 50% of the dopaminergic neurons of the substantia nigra [1].”
Background
The Origins of Oxidant Stress in Parkinson's Disease and Therapeutic Strategies
Surmeier, D. J., Guzmán, J. N., Sánchez-Padilla, J., & Goldberg, J. A. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3521 · Cited by 142
Cross-cultural adaptation and analysis of the psychometric properties of the Balance Evaluation Systems Test and MiniBESTest in the elderly and individuals with Parkinson's disease: application of the Rasch model
Maia, A. C., Rodrigues-de-Paula, F., Magalhães, L. D. C., & Teixeira, R. L. L. (2013) · Brazilian Journal of Physical Therapy · doi:10.1590/s1413-35552012005000085 · Cited by 143
Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?
McDonald, C., Newton, J. L., & Burn, D. J. (2016) · Movement Disorders · doi:10.1002/mds.26632 · Cited by 147
Pluripotent stem cell-based therapy for Parkinson’s disease: Current status and future prospects
Sonntag, K., Song, B., Lee, N., Jung, J. H., Cha, Y., Leblanc, P. R., Neff, C., Kong, S. W., Carter, B. S., Schweitzer, J., et al. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.04.005 · Cited by 144
TDP-43/FUS in motor neuron disease: Complexity and challenges
Guerrero, E. N., Wang, H., Mitra, J., Hegde, P. M., Stowell, S. E., Liachko, N. F., Kraemer, B. C., Garruto, R. M., Rao, K. S. J., & Hegde, M. L. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.09.004 · Cited by 146
“Despite its relatively low incidence compared to other neurodegenerative diseases like Alzheimer’s Disease (AD) (Hebert et al, 2013); or Parkinson’s disease (PD) (de Lau & Breteler, 2006); the devastating physiological effects and rapid lethality are the prominent features of ALS.”
Background
Altered Long Noncoding RNA Expression Precedes the Course of Parkinson’s Disease—a Preliminary Report
Kraus, T. F. J., Haider, M., Spanner, J., Steinmaurer, M., Dietinger, V., & Kretzschmar, H. A. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9854-x · Cited by 141
Gut Metagenomics-Derived Genes as Potential Biomarkers of Parkinson’s Disease
Qian, Y., Yang, X., Xu, S., Huang, P., Li, B., Du, J., He, Y., Su, B., Xu, L.-M., Wang, L., et al. (2020) · Brain · doi:10.1093/brain/awaa201 · Cited by 139
Emerging therapeutic potentials of dual‐acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases
Mathew, B., Parambi, D. G. T., Mathew, G. E., Uddin, M. S., Inasu, S. T., Kim, H., Marathakam, A., Unnikrishnan, M. K., & Carradori, S. (2019) · Archiv der Pharmazie · doi:10.1002/ardp.201900177 · Cited by 139
The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review
Suwijn, S. R., van Boheemen, C. J. M., de Haan, R. J., Tissingh, G., Booij, J., & de Bie, R. M. A. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0087-1 · Cited by 147
“Parkinsonism is most commonly caused by idiopathic Parkinson’s disease (PD) [1,2].”
Background
Back to the tubule: microtubule dynamics in Parkinson’s disease
Pellegrini, L., Wetzel, A., Grannò, S., Heaton, G., & Harvey, K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2351-6 · Cited by 147
Test-Retest Reliability and Minimal Detectable Change for the 10-Meter Walk Test in Older Adults With Parkinson's disease
Lang, J. T., Kassan, T. O., Devaney, L. L., Colón-Semenza, C., & Joseph, M. F. (2015) · Journal of Geriatric Physical Therapy · doi:10.1519/jpt.0000000000000068 · Cited by 140
Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders
Md, S., Bhattamisra, S. K., Zeeshan, F., Shahzad, N., Mujtaba, M. A., Meka, V. S., Radhakrishnan, A. K., Kesharwani, P., Baboota, S., & Ali, J. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.09.022 · Cited by 140
NfL as a biomarker for neurodegeneration and survival in Parkinson disease
Bäckström, D. C., Linder, J., Mo, S. J., Riklund, K., Zetterberg, H., Blennow, K., Forsgren, L., & Lenfeldt, N. (2020) · Neurology · doi:10.1212/wnl.0000000000010084 · Cited by 138
Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process
Moghadam, A. K., Charsouei, S., Bell, B., & Jabalameli, M. R. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0587-4 · Cited by 143
Falls in Parkinson's disease: Kinematic evidence for impaired head and trunk control
Cole, M. H., Silburn, P. A., Wood, J. M., Worringham, C. J., & Kerr, G. (2010) · Movement Disorders · doi:10.1002/mds.23292 · Cited by 136
Dietary and lifestyle variables in relation to incidence of Parkinson’s disease in Greece
Kyrozis, A., Ghika, A., Stathopoulos, P., Vassilopoulos, D., Trichopoulos, D., & Trichopoulou, A. (2013) · European Journal of Epidemiology · doi:10.1007/s10654-012-9760-0 · Cited by 140
Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies
Navarro, A., Boveris, A., Bández, M. J., Sánchez-del-Pino, M. J., Gómez, C., Muntané, G., & Ferrer, I. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.03.007 · Cited by 136
Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: Novel cytoprotective mechanism against oxidative damage
Lim, J. H., Kim, K., Kim, S. W., Hwang, O., & Choi, H. J. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.03.004 · Cited by 136
Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases
Duarte‐Neves, J., de Almeida, L. P., & Cavadas, C. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.022 · Cited by 144
An Intelligent Parkinson’s Disease Diagnostic System Based on a Chaotic Bacterial Foraging Optimization Enhanced Fuzzy KNN Approach
Cai, Z., Gu, J., Wen, C., Zhao, D., Huang, C., Huang, H., Tong, C., Li, J., & Chen, H. (2018) · Computational and Mathematical Methods in Medicine · doi:10.1155/2018/2396952 · Cited by 136
“Parkinson's disease (PD), a degenerative disorder of the central nervous system, is the second most common neurodegenerative disease [1].”
Background
M itochondrial DNA and primary mitochondrial dysfunction in P arkinson's disease
Giannoccaro, M. P., Morgia, C. L., Rizzo, G., & Carelli, V. (2017) · Movement Disorders · doi:10.1002/mds.26966 · Cited by 137
Resting-state functional reorganization in Parkinson's disease: An activation likelihood estimation meta-analysis
Tahmasian, M., Eickhoff, S. B., Giehl, K., Schwartz, F., Herz, D. M., Drzezga, A. E., van Eimeren, T., Laird, A. R., Fox, P. T., Khazaie, H., et al. (2017) · Cortex · doi:10.1016/j.cortex.2017.03.016 · Cited by 138
LC–MS-Based Urinary Metabolite Signatures in Idiopathic Parkinson’s Disease
Luan, H., Liu, L., Meng, N., Tang, Z., Chua, K.-K., Chen, L., Song, J., Mok, V., Xie, L.-X., Li, M., et al. (2014) · Journal of Proteome Research · doi:10.1021/pr500807t · Cited by 134
Risk of Parkinson disease after depression
Shen, C., Tsai, S., Perng, C., Kuo, B. I., & Yang, A. C. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a956ad · Cited by 134
The relationship between essential tremor and Parkinson's disease
Thenganatt, M. A., & Jankovic, J. J. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.032 · Cited by 133
“3%, increasing to 1% in individuals 60 years [2].”
Background
Long non-coding RNA MALAT1 contributes to cell apoptosis by sponging miR-124 in Parkinson disease
Liu, W., Zhang, Q., Zhang, J., Pan, W., Zhao, J., & Xu, Y. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0147-5 · Cited by 135
Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study
Sossi, V., de la Fuente‐Fernández, R., Schulzer, M., Troiano, A. R., Ruth, T. J., & Stoessl, A. J. (2007) · Annals of Neurology · doi:10.1002/ana.21204 · Cited by 133
The best medicine? The influence of physical activity and inactivity on Parkinson's disease
LaHue, S. C., Comella, C. L., & Tanner, C. M. (2016) · Movement Disorders · doi:10.1002/mds.26728 · Cited by 138
Early Degeneration of Both Dopaminergic and Serotonergic Axons – A Common Mechanism in Parkinson’s Disease
Grosch, J., Winkler, J., & Kohl, Z. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00293 · Cited by 132
Non-Motor Symptoms of Parkinson’s Disease and Their Impact on Quality of Life in a Cohort of Moroccan Patients
Tibar, H., Bayad, K. E., Bouhouche, A., Haddou, E. H. A. B., Benomar, A., Yahyaoui, M., Benazzouz, A., & Regragui, W. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00170 · Cited by 143
Diagnostic Value of 123I-Ioflupane and 123I-Iodobenzamide SPECT Scans in 248 Patients with Parkinsonian Syndromes
Vlaar, A. M. M., de Nijs, T., Kessels, A. G. H., Vreeling, F. W., Winogrodzka, A., Mess, W. H., Tromp, S. C., van Kroonenburgh, M. J. P. G., & Weber, W. E. J. (2008) · European Neurology · doi:10.1159/000115640 · Cited by 131
Direct neuronal reprogramming: Fast forward from new concepts toward therapeutic approaches
Bocchi, R., Masserdotti, G., & Götz, M. (2021) · Neuron · doi:10.1016/j.neuron.2021.11.023 · Cited by 135
Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease
Berg, D., Behnke, S., Seppi, K., Godau, J., Lerche, S., Mahlknecht, P., Liepelt‐Scarfone, I., Pausch, C., Schneider, N. R. E., Gaenslen, A., et al. (2012) · Movement Disorders · doi:10.1002/mds.25192 · Cited by 130
The role of monogenic genes in idiopathic Parkinson’s disease
Reed, X., Bandrés‐Ciga, S., Blauwendraat, C., & Cookson, M. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.11.012 · Cited by 137
The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease
Oñate, M., Catenaccio, A., Salvadores, N., Saquel, C., Martinez, A. N., Moreno‐González, I., Gamez, N., Rudolffi-Soto, P., Soto, C. A., Hetz, C. A., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0408-4 · Cited by 133
“The increase in life span and changes in life style predicts that the burden of PD will double over the next generation (Lau and Breteler, 2006).”
Background
Neurodegenerative Disorders and Sleep
Malhotra, R. K. (2018) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2017.09.006 · Cited by 127
Prevalence of malnutrition in Parkinson's disease: a systematic review
Sheard, J. M., Ash, S., Silburn, P. A., & Kerr, G. (2011) · Nutrition Reviews · doi:10.1111/j.1753-4887.2011.00413.x · Cited by 139
What causes the death of dopaminergic neurons in Parkinson’s disease?
Surmeier, D. J., Guzmán, J. N., Sánchez-Padilla, J., & Goldberg, J. A. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)83004-3 · Cited by 132
Six Novel Susceptibility Loci for Early-Onset Androgenetic Alopecia and Their Unexpected Association with Common Diseases
Li, R., Brockschmidt, F. F., Kiefer, A. K., Stefánsson, H., Nyholt, D. R., Song, K. S., Vermeulen, S. H. H. M., Kanoni, S., Glass, D., Medland, S. E., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002746 · Cited by 128
SOD1 and DJ-1 Converge at Nrf2 Pathway: A Clue for Antioxidant Therapeutic Potential in Neurodegeneration
Milani, P., Ambrosi, G., Gammoh, O. S., Blandini, F., & Cereda, C. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/836760 · Cited by 128
The ubiquitin proteasome system in glia and its role in neurodegenerative diseases
Jansen, A. H. P., Reits, E. A., & Hol, E. M. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00073 · Cited by 133
Treatment of Parkinson’s Disease through Personalized Medicine and Induced Pluripotent Stem Cells
Stoddard-Bennett, T., & Pera, R. A. R. (2019) · Cells · doi:10.3390/cells8010026 · Cited by 137
“PD is the second most common neurodegenerative disease, debilitating 1% of the population over the last 60 years [1].”
Background
Brain mitochondrial dysfunction and oxidative damage in Parkinson’s disease
Navarro, A., & Boveris, A. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9250-6 · Cited by 126
“Parkinson’s disease is an old-age neurodegenerative disease with a prevalence of 0.3% in the entire population, affecting more than 1% of the humans over 60 years of age (de Lau and Breteler 2006).”
BackgroundInfluential
Association of Blood Pressure and Hypertension With the Risk of Parkinson Disease
Qiu, C., Hu, G., Kivipelto, M., Laatikainen, T. K., Antikaínen, R., Fratiglioni, L., Jousilahti, P., & Tuomilehto, J. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.171249 · Cited by 126
Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database
McLean, G., Hindle, J. V., Guthrie, B., & Mercer, S. W. (2017) · BMC Neurology · doi:10.1186/s12883-017-0904-4 · Cited by 129
Exploring causality of the association between smoking and Parkinson’s disease
Gallo, V., Vineis, P., Cancellieri, M., Chiodini, P., Barker, R. A., Brayne, C., Pearce, N. E., Vermeulen, R. C. H., Panico, S., Bueno-de-Mesquita, B. H., et al. (2018) · International Journal of Epidemiology · doi:10.1093/ije/dyy230 · Cited by 131
Automated detection of Parkinson's disease using minimum average maximum tree and singular value decomposition method with vowels
Tuncer, T., Doğan, Ş., & Acharya, U. R. (2019) · Journal of Applied Biomedicine · doi:10.1016/j.bbe.2019.05.006 · Cited by 126
Potential Roles of Exosomes in Parkinson’s Disease: From Pathogenesis, Diagnosis, and Treatment to Prognosis
Yu, H., Sun, T., An, J., Wen, L., Liu, F., Bu, Z., Cui, Y., & Feng, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00086 · Cited by 130
The effect of LRRK2 loss-of-function variants in humans
Whiffin, N., Armean, I. M., Kleinman, A., Marshall, J. L., Minikel, E. V., Goodrich, J. K., Quaife, N. M., Cole, J. B., Wang, Q. S., Karczewski, K. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0893-5 · Cited by 126
Disease Penetrance of Late-Onset Parkinsonism
Trinh, J., Guella, I., & Farrer, M. J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1909 · Cited by 125
Repetitive transcranial magnetic stimulation therapy for motor recovery in Parkinson's disease: A Meta‐analysis
Yang, C., Guo, Z., Peng, H., Xing, G., Chen, H., McClure, M. A., He, B., He, L., Du, F., Xiong, L., et al. (2018) · Brain and Behavior · doi:10.1002/brb3.1132 · Cited by 126
Single-cell transcriptome and TCR profiling reveal activated and expanded T cell populations in Parkinson’s disease
Wang, P., Yao, L., Luo, M., Zhou, W., Jin, X., Xu, Z., Shi, Y., Li, Y., Xu, C., Cheng, R., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00280-3 · Cited by 129
Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease
Aasly, J. O., Vilariño‐Güell, C., Dächsel, J. C., Webber, P. J., West, A. B., Haugarvoll, K., Johansen, K. K., Toft, M., Nutt, J. G., Payami, H., et al. (2010) · Movement Disorders · doi:10.1002/mds.23265 · Cited by 125
Amentoflavone protects dopaminergic neurons in MPTP-induced Parkinson's disease model mice through PI3K/Akt and ERK signaling pathways
Cao, Q. C., Qin, L., Huang, F., Wang, X., Liu, Y., Shi, H., Wu, H., Zhang, B., Chen, Z., & Wu, X. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.01.019 · Cited by 125
MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting α-synuclein expression in MPTP-induced Parkinson’s disease mouse
Wang, Z.-H., Zhang, J.-L., Duan, Y.-L., Zhang, Q., Li, G.-F., & Zheng, D.-L. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.08.025 · Cited by 127
Integrated molecular landscape of Parkinson’s disease
Klemann, C. J. H. M., Martens, G. J. M., Sharma, M., Martens, M. B., Ole Isacson, A., Gasser, T., Visser, J. E., & Poelmans, G. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-017-0015-3 · Cited by 129
Downregulation of blood serum microRNA 29 family in patients with Parkinson’s disease
Bai, X., Tang, Y., Yu, M., Wu, L., Liu, F., Ni, J., Wang, Z., Wang, J., Fei, J., Wang, W., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03887-3 · Cited by 124
Assessing visual attributes of handwriting for prediction of neurological disorders—A case study on Parkinson’s disease
Moetesum, M., Siddiqi, I., Vincent, N., & Cloppet, F. (2018) · Pattern Recognition Letters · doi:10.1016/j.patrec.2018.04.008 · Cited by 125
A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism
Book, A., Guella, I., Candido, T., Brice, A., Hattori, N., Jeon, B., & Farrer, M. J. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01021 · Cited by 121
“3% increasing to 1% in those >60 and 4% >80 years (1).”
Background
The potential use of mesenchymal stem cells and their exosomes in Parkinson’s disease treatment
Mosaddeghi-Heris, R., Shirvaliloo, M., Abbaspour‐Aghdam, S., Hazrati, A., Shariati, A., Youshanlouei, H. R., Jadidi‐Niaragh, F., Valizadeh, H., & Ahmadi, M. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03050-4 · Cited by 123
Quercetin in brain diseases: Potential and limits
Dajas, F., Abin‐Carriquiry, J. A., Arredondo, F., Blasina, F., Echeverry, C., Martinez, M. M., Rivera, F., & Vaamonde, L. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.07.002 · Cited by 126
Risk of Parkinson's disease following severe constipation: A nationwide population-based cohort study
Lin, C., Lin, J., Liu, Y., Chang, C., & Wu, R. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.09.026 · Cited by 122
Sirt3 protects dopaminergic neurons from mitochondrial oxidative stress
Shi, H., Deng, H., Gius, D. R., Schumacker, P. T., Surmeier, D. J., & Ma, Y. C. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx100 · Cited by 126
Glucose Metabolic Dysfunction in Neurodegenerative Diseases—New Mechanistic Insights and the Potential of Hypoxia as a Prospective Therapy Targeting Metabolic Reprogramming
Han, R., Liang, J., & Zhou, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115887 · Cited by 125
Associations between B Vitamins and Parkinson’s Disease
Shen, L. (2015) · Nutrients · doi:10.3390/nu7095333 · Cited by 121
Selenoprotein T Exerts an Essential Oxidoreductase Activity That Protects Dopaminergic Neurons in Mouse Models of Parkinson's Disease
Boukhzar, L., Hamieh, A., Cartier, D., Tanguy, Y., Alsharif, I., Castex, M., Arabo, A., Hajji, S. E., Bonnet, J., Errami, M., et al. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6478 · Cited by 119
Neuroprotective Effect of Ropinirole Lipid Nanoparticles Enriched Hydrogel for Parkinson’s Disease: In Vitro, Ex Vivo, Pharmacokinetic and Pharmacodynamic Evaluation
Dudhipala, N. R., & Gorre, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050448 · Cited by 121
“PD is characterized by tremor, rigidity, postural abnormalities, stooped posture, bradykinesia, akinesia and festinating gait [3].”
Background
Animal models of Parkinson's disease: An updated overview
Gubellini, P., & Kachidian, P. (2015) · Revue Neurologique · doi:10.1016/j.neurol.2015.07.011 · Cited by 128
The Role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic Review
Wen, K., Milić, J., El‐Khodor, B. F., Dhana, K., Nano, J., Pulido, T., Kraja, B., Začiragić, A., Bramer, W. M., Troup, J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167201 · Cited by 130

Authors: de Lau, L. M., & Breteler, M. M.
Affiliations: Erasmus MC (NL)
Corresponding author: Breteler, Monique MB
ORCID: Breteler, Monique MB
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2006-06
Volume: 5
Issue: 6
Pages: 525-535
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(06)70471-9
OpenAlex: W2134886133
Cited by: 4,110
References: 119
Citations by year: 2026: 108 · 2025: 172 · 2024: 229 · 2023: 230 · 2022: 307 · 2021: 315 · 2020: 337 · 2019: 290 · 2018: 301 · 2017: 284 · 2016: 259 · 2015: 288 · 2014: 232 · 2013: 200 · 2012: 159
FWCI: 7.02
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Parkinson's disease, prevalence, incidence, risk factors, prognosis, genetic susceptibility, gene-environment interaction, neurodegeneration, prospective cohort
MeSH terms: Age Factors, Humans, Parkinson Disease, Prognosis, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks